NCT06710158

Study of SC-102 in Patients With Advanced Solid Tumors

Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-102 in Subjects With Advanced or Metastatic Solid Tumors That Express EphA2

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Tianjin ConjuStar Biologics Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors

Detailed description

SC-102 is a peptide drug conjugate (PDC) consisting of an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolysable linker. This phase I multi-center, open-label first-in-human trial, including a dose escalation study and a dose expansion study, will evaluate SC-102 administrated once weekly or biweekly as a single agent in patients with advanced solid tumors. The dose escalation study is primarily designed to assess the safety and tolerability of SC-102 and to determine the recommended dose(s) for the dose expansion study. The dose expansion study is designed with the primary objective of evaluating the clinical activity of SC-102.

Conditions

• Advanced Solid Cancers

Interventions

Type	Name	Description
DRUG	SC-102	SC-102 is a peptide drug conjugate (PDC) consisting an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolyzable linker.

Timeline

• Start date: 2024-12-05
• Primary completion: 2026-12-01
• Completion: 2027-06-01
• First posted: 2024-11-29
• Last updated: 2025-07-29

Locations

1 site across 1 country: China